E-course: The role of risk stratification of prostate cancer
This is the third episode of the new series “Prostate Cancer Screening: PRAISE U training toolbox” organised by the European School of Urology, the EAU Policy Office, and the PRAISE-U Consortium. This e-course introduction will provide a recap of the previous episodes.
The e-course examines the emerging role of risk stratification in prostate cancer (PCa) screening, highlighting how predictive models and biomarkers are reshaping screening strategies and clinical decision-making. The experts will discuss how various factors (e.g., PSA levels, MRI findings, genetic markers, clinical data, etc.) are integrated into risk models to refine screening recommendations. A presentation will also cover long-term risk assessment and the impact of age, family history, and PSA thresholds on screening protocols.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
Additionally, the e-course will explore the growing role of genetic testing in PCa risk prediction, including the significance of BRCA1/2 mutations, Lynch syndrome, and other genetic risk calculators. The presenters will discuss how genetic information is incorporated into predictive models and its implications for personalised screening and treatment.
The e-course will also address the challenges and benefits of integrating genetic testing into clinical practice, as well as future advancements in PCa risk assessment.
Speakers:
- Assoc. Prof. R. Van Den Bergh (NL)
- Prof. H. Van Poppel (BE)
- Prof. A.P. Auvinen (FI)
- Dr. E.A.M. Heijnsdijk (NL)
- Drs. S.F. Westerhout (NL)
- Dr. J. Lakes (DE)
This e-course is brought to you in collaboration with the EAU Policy Office and the PRAISE-U Consortium.